All In Biotech

Drug Trial Radar · NCT06462404

A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 1

A Randomized, Double-Blind, Single-Dose, 5-Period Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Subjects With Narcolepsy Type 1

Last checked: Nov 19, 2026Latest source record: Jun 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

22

Actual

Start

Jun 20, 2024

Primary completion

Mar 17, 2025

Study completion Mar 17, 2025

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
First posted
Jun 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the efficacy of single oral doses of E2086 compared to placebo in the treatment of excessive daytime sleepiness (EDS) as assessed by the Maintenance of Wakefulness Test (MWT) in adult participants with narcolepsy type 1 (NT1).

Conditions

  • Narcolepsy Type 1 (NT1)

Interventions

  • E2086Drug

    E2086 oral tablets.

  • E2086 PlaceboDrug

    E2086 matching placebo tablet.

  • Active ComparatorDrug

    Active comparator oral tablets.

  • Active Comparator PlaceboDrug

    Active comparator matching placebo tablet.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Sleep Latency (MSL) as Assessed by the 4 Maintenance of Wakefulness Tests (MWTs) for E2086 Versus Placebo at Day 1Time frame: At Day 1
  2. MSL as Assessed by the 4 MWTs for E2086 Versus Placebo at Day 5Time frame: At Day 5
  3. MSL as Assessed by the 4 MWTs for E2086 Versus Placebo at Day 9Time frame: At Day 9
  4. MSL as Assessed by the 4 MWTs for E2086 Versus Placebo at Day 13Time frame: At Day 13
  5. MSL as Assessed by the 4 MWTs for E2086 Versus Placebo at Day 17Time frame: At Day 17

Locations

14 sites in 2 countries. Site status is shown where the registry gives one.

  • SDS Clinical Trials

    Santa Ana, California

  • PharmaDev Clinical Research

    Miami, Florida

  • Sleep Practioners, LLC

    Macon, Georgia

  • Clinical Research Institute

    Stockbridge, Georgia

  • Sound Asleep Research, Inc.

    Lansing, Michigan

  • Research Carolina Elite

    Denver, North Carolina

  • Medical Care Inc.

    Goldsboro, North Carolina

  • Advances Repiratory and Sleep Medicine

    Greensboro, North Carolina

  • Intrepid Research, LLC

    Cincinnati, Ohio

  • Bogan Sleep Consultants, LLC

    Columbia, South Carolina

  • Sleep Therapy and Research Center

    San Antonio, Texas

  • Comprehensive Sleep Medicine Associates

    Sugar Land, Texas

  • AMDX Inc.

    Markham, Ontario, Canada

  • Jodha Tishon Inc

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.